您的位置:首页  > 论文页面

PD-1/PD-L1阻断剂的临床研究进展

发表时间:2018-09-14  浏览量:813  下载量:100
全部作者: 葛驾,张发明
作者单位: 武汉大学药学院
摘 要: 程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)是一种抑制性免疫受体,它通过与配体PD-L1和PD-L2结合,抑制T细胞的增殖及其介导的免疫应答。阻断PD-1/PD-L1信号通路能够逆转这一过程,从而增强抗肿瘤免疫活性。目前,已经成功开发了通过增强T细胞功能来阻断PD-1/PD-L1途径的单克隆抗体(monoclonal antibodies,mAbs)用于癌症免疫治疗。临床研究表明,PD-1/PD-L1阻断剂临床试验显示出非常高的响应率,特别是对于黑色素瘤、非小细胞肺癌、肾细胞癌和膀胱癌。PD-1/PD-L1阻断剂联合疗法能改善自身的不足,并正在广泛研究之中。本文旨在总结与展望PD-1/PD-L1阻断剂的临床研究情况。
关 键 词: 生物药物学;肿瘤;综述;程序性细胞死亡蛋白1(PD-1);程序性细胞死亡蛋白配体1(PD-L1);免疫治疗
Title: Clinical research progress of PD-1/PD-L1 blockade agents
Author: GE Jia, ZHANG Faming
Organization: School of Pharmaceutical Sciences, Wuhan University
Abstract: Programmed cell death protein 1 (PD-1) is an inhibitory immune receptor, which inhibits T cell proliferation and its mediated immune response by binding to its ligands, PD-L1 and PD-L2. Blocking the PD-1/PD-L1 signaling pathway can reverse this process and enhance antitumor immunity. Monoclonal antibodies (mAbs) that block the PD-1/PD-L1 pathway by enhancing T cell function have been developed for cancer immunotherapy. Clinical trials with PD-1/PD-L1 blockade angents have shown impressive response rates in patients, especially for melanoma, non-small-cell lung cancer, renal cell carcinoma and bladder cancer. PD-1/PD-L1 blockade angents combination therapies which can improve its own deficiency are being extensively studied. This paper aims to summarize and prospect the clinical study of PD-1/PD-L1 blockade angents.
Key words: biopharmaceutics; cancer; review; programmed cell death protein 1 (PD-1); programmed cell death protein ligand 1 (PD-L1); immunotherapy
发表期数: 2018年9月第17期
引用格式: 葛驾,张发明. PD-1/PD-L1阻断剂的临床研究进展[J]. 中国科技论文在线精品论文,2018,11(17):1734-1741.
 
0 评论数 0
暂无评论
友情链接